Nephrotoxicity comparison of two commercially available generic vancomycin products

Area of Science:

• Nephrology
• Pharmacology
• Clinical Pharmacy

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Nephrotoxicity is a significant adverse effect associated with vancomycin therapy.
• Comparative data on the nephrotoxic potential of different vancomycin formulations are lacking.

Purpose of the Study:

• To compare the incidence of nephrotoxicity between two vancomycin products (Pfizer vs. Hospira).
• To evaluate the impact of vancomycin product type on secondary outcomes including renal replacement therapy, hospital stay, and mortality.

Main Methods:

• Single-center, retrospective, matched-cohort study.
• Adult patients receiving either Pfizer or Hospira vancomycin for their entire treatment course.
• Patients matched based on pre-existing nephrotoxicity risk factors.
• Nephrotoxicity assessed using 2009 consensus guidelines, AKIN, and RIFLE criteria.

Main Results:

• 146 matched pairs (n=292) were analyzed with no significant differences in baseline characteristics.
• Nephrotoxicity rates were similar across groups regardless of the definition used (e.g., RIFLE: 10.3% Pfizer vs. 11.6% Hospira).
• No statistically significant differences were observed in secondary outcomes or multivariate analysis of nephrotoxicity risk factors.

Conclusions:

• The type of vancomycin product (Pfizer or Hospira) does not appear to influence the frequency of nephrotoxicity.
• Vancomycin product formulation was not an independent risk factor for developing nephrotoxicity.
• Further research is needed to confirm these findings in diverse patient populations and with other vancomycin products.